CFLT Insider Notice: 953 Shares to Be Sold; Recent 10b5-1 Sales Disclosed
Rhea-AI Filing Summary
Form 144 filing for Confluent, Inc. (CFLT) reports a proposed sale of 953 common shares through Morgan Stanley Smith Barney with an aggregate market value of $17,964.05 and an approximate sale date of 08/28/2025. The filer acquired these shares on 09/26/2014 as an in-kind distribution post-IPO and lists total outstanding shares of 291,931,187.
The filing also discloses recent 10b5-1 sales on 06/05/2025: THE VISHRIA REVOCABLE TRUST sold 15,000 shares for $375,000 and THE KHAKAL TRUST sold 476 shares for $11,900. The signer certifies no undisclosed material adverse information and references reliance on trading-plan provisions where applicable.
Positive
- Regulatory compliance—the filing provides required Form 144 disclosures including broker, acquisition date, and certification
- Transparency on prior activity—recent 10b5-1 sales on 06/05/2025 are disclosed with amounts and proceeds
Negative
- Insider-related dispositions—trust accounts sold 15,476 shares in the past three months, which may attract investor attention despite being small versus total outstanding
Insights
TL;DR Routine Rule 144 notice; small proposed sale versus overall float and prior 10b5-1 activity disclosed.
This Form 144 documents a compliance notice for a proposed sale of 953 shares valued at $17,964.05, representing an immaterial fraction of the 291,931,187 shares outstanding. The filing properly states acquisition history (in-kind post-IPO distribution, 9/26/2014) and names the executing broker. The inclusion of recent 10b5-1 sales on 6/5/2025 totaling 15,476 shares provides additional context on prior insider-related dispositions. For investors, the filing is a transparency item rather than a signal of material change to company fundamentals.
TL;DR Disclosure aligns with regulatory requirements; shows use of prearranged plans for orderly dispositions.
The notice includes the standard certification that the seller is unaware of undisclosed material adverse information and references Rule 10b5-1 planning where applicable. Naming the broker and providing acquisition details (in-kind distribution post-IPO) meet Form 144 expectations. The recent 10b5-1 sales by trusts are documented with gross proceeds, which aids governance transparency. There is no disclosure here of any unusual insider conduct or deviations from planned sales.
FAQ
What does Confluent's (CFLT) Form 144 report?
Who is the broker listed on the Form 144 for CFLT?
When were the shares to be sold originally acquired?
Were there recent insider or trust sales disclosed for CFLT?
How many shares does Confluent have outstanding per the filing?